EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT 11.18.2024

Full Press ReleaseSEC FilingsOur EYPT Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - EyePoint Provides Company Update and Anticipated Development Milestones for 2025

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.08.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

WATERTOWN, Mass.,Nov. 18, 2024(GLOBE NEWSWIRE) --EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 23,600 shares ofEyePoint Pharmaceuticalscommon stock to four new employees. The stock options were granted onNovember 15, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment withEyePoint Pharmaceuticalsin accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of$9.17per share, the closing price of EyePoint Pharmaceuticals’ common stock onNovember 15, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service withEyePoint Pharmaceuticalsthrough the applicable vesting dates.

AboutEyePoint Pharmaceuticals

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert ETM technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYUTM (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert ETM. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older inthe United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert ETM to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across fourU.S.FDA approved products.EyePoint Pharmaceuticalsis headquartered inWatertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside ofChina,Macao,Hong KongandTaiwan.

DURAVYUTM has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

ForEyePoint Pharmaceuticals:

Investors:Christina TartagliaPrecision AQ (formerly Stern IR)Direct: 212-698-8700christina.tartaglia@precisionaq.com

Media Contact:Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com

Primary Logo

Source: EyePoint Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com